#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner: Gibbs, Terra C.

Group Art Unit: 1635

In re PATENT APPLICATION of
Applicant(s): Ulrich Bogdahn et al.

Serial No.: 10/597,813

Filed: April 13, 2007

For: INHIBITORS OF TGF-R SIGNALING FOR TREATMENT OF CNS DISORDERS

Attorney Docket: JCLA21512

### **DECLARATION TRAVERSING REJECTIONS UNDER 37 CFR \$1.132**

Dear Sir,

As below named inventor(s) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

## INHIBITORS OF TGF-R SIGNALING FOR TREATMENT OF CNS DISORDERS

The specification of which was filed on April 13, 2007 as Application Serial No.:10/597,813.

I (We) hereby declare that in order to overcome the enablement requirement rejections, I (We) provide the following statements and information.

I (Wc) declare that the EMBL database entry

(http://ensembl.org/Homo\_sapiens/Transcript/Sequence\_cDNA?g=ENSG00000163513:t=ENST0 0000295754) shows cDNA sequence of the TGF-βR<sub>II</sub> gene with the start codon ATG at position 383.

I (We) hereby declare that all statements made herein of our own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful, false statements may jeopardize the validity of the application or any patent issued thereon.

Full Name:				
Signature	ULRICH BOGIAHN	Date :	28/6/201	
Signature:	LUDWIG AIGNER	Date:		
Signature :	FRANK-PETER WACHS	Date:		
Signature :	BEATE WINNER	Date:		
Signature:	JÜRGEN WINKLER	Date :		

### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner: Gibbs, Terra C.

In re PATENT APPLICATION of
Applicant(s): Ulrich Bogdahn et al.

Serial No.: 10/597,813

Filed: April 13, 2007

For: INHIBITORS OF TGF-R SIGNALING FOR TREATMENT OF CNS DISORDERS

Attorney Docket: JCLA21512

## DECLARATION TRAVERSING REJECTIONS UNDER 37 CFR \$1.132

Dear Sir,

As below named inventor(s) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

### INHIBITORS OF TGF-R SIGNALING FOR TREATMENT OF CNS DISORDERS

The specification of which was filed on April 13, 2007 as Application Serial No.:10/597,813.

I (We) hereby declare that in order to overcome the enablement requirement rejections, I (We) provide the following statements and information.

I (We) declare that the EMBL database entry

(http://ensembl.org/Homo\_sapiens/Transcript/Sequence\_cDNA?g=ENSG00000163513;t=ENST0 0000295754) shows cDNA sequence of the TGF-βR<sub>II</sub> gene with the start codon ATG at position 383.

In addition, the pdf file of the above webpage is also submitted.

ورورية مز

I (We) hereby declare that all statements made herein of our own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful, false statements may jeopardize the validity of the application or any patent issued thereon.

Signature:

Date:

ULRICH BOGDAHN

Signature:

LUDWIG AIGNER

Date:

FRANK-PETER WACHS

Date:

Date:

Date:

Date:

Date:

Date:

Date:

Signature : JÜRGEN WINKLER

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner: Gibbs, Terra C.

Group Art Unit: 1635

In re PATENT APPLICATION of Applicant(s): Ulrich Bogdahn et al. )

Serial No.: 10/597.813 )

Filed: April 13, 2007 )

For: INHIBITORS OF TGF-R SIGNALING FOR TREATMENT OF CNS DISORDERS )

Attorney Docket: JCLA21512

### **DECLARATION TRAVERSING REJECTIONS UNDER 37 CFR §1.132**

Dear Sir,

As below named inventor(s) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

## INHIBITORS OF TGF-R SIGNALING FOR TREATMENT OF CNS DISORDERS

The specification of which was filed on April 13, 2007 as Application Serial No.:10/597,813.

I (We) hereby declare that in order to overcome the enablement requirement rejections, I (We) provide the following statements and information.

I (We) declare that the EMBL database entry

(http://ensembl.org/Homo\_sapiens/Transcript/Sequence\_cDNA?g=ENSG00000163513:t=ENST0 0000295754) shows cDNA sequence of the TGF-βR<sub>II</sub> gene with the start codon ATG at position 383.

I (We) hereby declare that all statements made herein of our own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful, false statements may jeopardize the validity of the application or any patent issued thereon.

Full Name:		·	
Signature:	ULRICH BOGDAHN	Date:	
Signature:	LUDWIG AIGNER	_ Date :	
Signature:	Or. Machis FRANK-PETER WACHS	_Date :	1 2 JUL 2010
Signature:	BEATE WINNER	_Date :	
Signature :	JÜRGEN WINKLER	_Date :	

# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner: Gibbs, Terra C.

Group Art Unit: 1635

In re PATENT APPLICATION of
Applicant(s): Ulrich Bogdahn et al.

Serial No.: 10/597,813

Filed: April 13, 2007

For: INHIBITORS OF TGF-R SIGNALING FOR TREATMENT OF CNS DISORDERS

Attorney Docket: JCLA21512

## DECLARATION TRAVERSING REJECTIONS UNDER 37 CFR \$1.132

Dear Sir,

As below named inventor(s) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

# INHIBITORS OF TGF-R SIGNALING FOR TREATMENT OF CNS DISORDERS

The specification of which was filed on April 13, 2007 as Application Serial No.:10/597,813.

I (We) hereby declare that in order to overcome the enablement requirement rejections, I (We) provide the following statements and information.

I (We) declare that the EMBL database entry

(http://ensembl.org/Homo\_sapiens/Transcript/Sequence\_cDNA?g=ENSG00000163513;t=ENST0 0000295754) shows cDNA sequence of the TGF-βR<sub>II</sub> gene with the start codon ATG at position 383.

I (We) hereby declare that all statements made herein of our own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful, false statements may jeopardize the validity of the application or any patent issued thereon.

Full	Name:			
	Signature:	ULRICH BOGDAHN	Date: _	
	Signature:	LUDWIG AIGNER	Date :	
	Signature:	FRANK-PETER WACHS	Date: _	
	Signature :	B.W.WQ. BEATE WINNER	Date:	12.7.10
	Signature:	JÜRGEN WINKLER	Date : _	

# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner: Gibbs, Terra C.

In re PATENT APPLICATION of
Applicant(s): Ulrich Bogdahn et al.

Serial No.: 10/597,813

Filed: April 13, 2007

For: INHIBITORS OF TGF-R SIGNALING FOR TREATMENT OF CNS DISORDERS

Attorney Docket: JCLA21512

## DECLARATION TRAVERSING REJECTIONS UNDER 37 CFR §1.132

Dear Sir,

As below named inventor(s) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

# INHIBITORS OF TGF-R SIGNALING FOR TREATMENT OF CNS DISORDERS

The specification of which was filed on April 13, 2007 as Application Serial No.:10/597,813.

I (We) hereby declare that in order to overcome the enablement requirement rejections, I (We) provide the following statements and information.

I (We) declare that the EMBL database entry

(http://ensembl.org/Homo\_sapiens/Transcript/Sequence\_cDNA?g=ENSG000000163513;t=ENST0 0000295754) shows cDNA sequence of the TGF- $\beta R_{II}$  gene with the start codon ATG at position 383.

5.2

Application No.: 10/597,813

Docket No.: JCLA21512

I (We) hereby declare that all statements made herein of our own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful, false statements may jeopardize the validity of the application or any patent issued thereon.

Neurologie Erlangen

Full Name: Signature: ULRICH BOGDAHN Date : \_\_\_\_\_ Signature: LUDWIG AIGNER Date : \_\_\_\_\_ Signature: \_ FRANK-PETER WACHS Date: \_ Signature: BEATE WINNER Signature: ÜRGEN WINKLER